tirzepatide china approves Eli Lilly's blockbuster diabetes drug Eli Lilly's weight loss drug

Given the benign mechanism of action and the excellent safety profile observed in trials, serious long-term risks seem unlikely

In addition, no new safety signals were observed in post hoc analyses compared with what was observed in the main SOUL trial and other previous trials, according to Rodica Pop-Busui, MD, PhD , the Jordan Schnitzer-endowed Chair in Diabetes

Anaerobic bacterial activity on these residues produces hydrogen sulfide and other volatile sulfur compounds

Pediatric intensive care unit treatment alters the diversity and composition of the gut microbiota and antimicrobial resistance gene expression in critically ill children